Cibus Revenue and Competitors

Location

$131.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cibus's estimated annual revenue is currently $72.3M per year.(i)
  • Cibus received $70.0M in venture funding in June 2018.
  • Cibus's estimated revenue per employee is $217,000
  • Cibus's total funding is $131.3M.

Employee Data

  • Cibus has 333 Employees.(i)
  • Cibus grew their employee count by 21% last year.

Cibus's People

NameTitleEmail/Phone
1
Co-Founder, CEO and ChairmanReveal Email/Phone
2
SVP, Cibus - President & CEO, NucelisReveal Email/Phone
3
VP Business DevelopmentReveal Email/Phone
4
EVP Strategy and Sustainable IngredientsReveal Email/Phone
5
SVP, ResearchReveal Email/Phone
6
General CounselReveal Email/Phone
7
VP, Seed & TraitsReveal Email/Phone
8
VP, ProductionReveal Email/Phone
9
Co-Founder and Chief Scientific Officer & EVPReveal Email/Phone
10
Director Corporate AccountingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.4M643%N/AN/A
Add Company

What Is Cibus?

Cibus has developed plant and microbial platforms enabling it to become a world leader in precision gene editing, generally, and advanced non-transgenic breeding, specifically. The Rapid Trait Development System (RTDS), its proprietary technology for non-transgenic breeding, enables site-specific edits of native genes with no introduction of foreign DNA. The precise and predictable outcomes can replicate products developed using traditional mutagenesis and are identical to those that could occur in nature, given enough time. Consequently, these plants are not considered transgenic, the key attributes of GMO crops. Cibus has launched its first commercial crop, SU Canola, a non-transgenic canola tolerant to sulfonylurea herbicides in the United States, and has received regulatory approval in Canada, putting the trait on track to launch there after 2016. Over the next 10 years Cibus expects to develop new, non-transgenic traits for most major crops. The Cibus family includes the team of founding scientists and executives, and has grown to more than 100 employees who provide extensive backgrounds across a number of disciplines. Cibus is the parent company of Nucelis, which is focused on the cosmetic, nutraceutical and lubricant additive segments through its RTDS-based yeast production process (ypRTDS) to make squalane. Nucelis squalane process and product is both GMO-free and sustainable. The ypRTDS platform offers a wide variety of additional specialty chemical applications. Nucelis is built on Cibus platform of unique, patented technology for optimizing cell structure and function. Nucelis vision is to change the way industry develops bio-based chemicals by utilizing nature's own production factories such as plants, yeast, and bacteria. Cibus is located in three major centers in the U.S. and Europe.

keywords:N/A

$131.3M

Total Funding

333

Number of Employees

$72.3M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cibus News

2022-04-17 - ADM Capital Europe Seeks $800 Million for Food and ...

The London-based investment firm is aiming to raise $600 million for Cibus Fund II LP, which takes majority and minority positions in...

2022-04-17 - La Mozzarella di Bufala Campana Dop raddoppia a Cibus

Proprio al Cibus il Consorzio presenterà il nuovo studio di mercato sulla Mozzarella di Bufala Campana Dop, realizzato da Nomisma, e l'anteprima...

2022-04-06 - The City View: Rob Appleby, CIO of the Cibus Fund, on the future of food, food tech, and supply chain disruption

Today Andy Silvester chats to Rob Appleby, co-founder and Chief Investment Officer of the Cibus Fund, a London-based private equity platform...

2018-06-26 - Cibus Raises $70m Series C for Gene Editing “Indistinguishable” from Traditional Plant Breeding

**Stay tuned for further updates on the differences between Cibus’ RTDS process and other gene editing tools such as CRISPR Cas-9** Cibus, a company using gene editing technology to breed crops with improved characteristics, has raised $70 million in Series C funding. Fidelity Management and R ...

2018-06-26 - Cibus Raises $70M in Series C Funding

Cibus, a San Diego, CA-based leader in the application of gene editing technologies for directed mutagenesis, raised $70m in Series C funding. The round was led by Fidelity Management and Research Company and joined by Alexandria Venture Investments and Cormorant Asset Management. The company ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$112.4M3339%N/A
#2
$87.7M334N/AN/A
#3
$59.6M335-16%$188.4M
#4
$2.4M33731%$446M
#5
$85.2M3398%N/A

Cibus Funding

DateAmountRoundLead InvestorsReference
2018-06-27$70.0MCFidelity Management and Research CompanyArticle